Chemical analysis of synthetic cannabinoids as designer drugs in herbal products

Forensic Science International

Volumn 198, Issue 1-3, 2010, Pages 31-38

  Uchiyama, Nahoko ^a   Kikura Hanajiri, Ruri ^a   Ogata, Jun ^a   Goda, Yukihiro ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Cannabicyclohexanol; CP 47,497; JWH 018; JWH 073; Oleamide; Synthetic cannabinoid

Indexed keywords

1 NAPHTHALENYL(1 PENTYL 1H INDOL 3 YL)METHANONE; 3 [2 HYDROXY 4 (2 METHYLOCTAN 2 YL)PHENYL]CYCLOHEXAN 1 OL; CANNABICYCLOHEXANOL; CANNABINOID; HERBACEOUS AGENT; OLEAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; JAPAN; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 77952291222     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2010.01.004     Document Type: Article

References (29)

1. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Haishima Y., Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem. Pharm. Bull. 2009, 57:439-441.
2. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Goda Y. Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol. 2009, 27:61-66.
3. C.A. Harbert, M.R. Johnson, L.S.Jr. Melvin, 3-[Hydroxy-4-(substituted)-phenyl]-cycloalkanone and cycloalkanol derivatives, DE Patent 2839836, 1979.
4. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 1993, 265:218-226.
5. Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 1992, 260:201-209.
6. Melvin L.S., Milne G.M., Johnson M.R., Subramaniam B., Wilken G.H., Howlett A.C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 1993, 44:1008-1015.
7. Thomas B.F., Compton D.R., Martin B.R. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J. Pharmacol. Exp. Ther. 1990, 255:624-630.
8. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 1991, 40:471-478.
9. Wiley J.L., Compton D.R., Dai D., Lainton J.A., Phillips M., Huffman J.W., Martin B.R. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther. 1998, 285:995-1004.
10. 2 receptor binding. Drug Alcohol Depend. 2000, 60:133-140.
11. Huffman J.W. Cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem. 1999, 6:705-720.
12. 1 cannabinoid receptor. Bioorg. Med. Chem. 2003, 11:539-549.
13. Auwärter V., Dresen S., Weinmann W., Müller M., Pütz M., Ferreirós N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?. J. Mass. Spectrom. 2009, 44:832-837.
14. Zweiundzwanzigste Verordnung, zur Änderung betäubungsmittelrechtlicher Vorschriften (2009), Germany, BGBl I Nr. 3 vom 21.01.2009, 22, BtMÄndV vom 19, Januar 2009, S. 49-50. (Accessed January 2009) http://www.bgblportal.de/BGBL/bgbl1f/bgbl109s0049.pdf
15. EMCDDA Action on new drugs briefing paper: Understanding the 'Spice' phenomenon (a report from an EMCDDA expert meeting, 6 March 2009, Lisbon). (Accessed July 2009) http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_EMCDDA_Understanding%20the%20'Spice'%20phenomenon_3Update%2020090706.pdf.
16. Kikura-Hanajiri R., Kawamura M., Uchiyama N., Ogata J., Kamakura H., Saisho K., Goda Y. Analytical data of designated substances (Shitei-Yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan, part I: GC-MS and LC-MS. Yakugaku Zasshi 2008, 128:971-979.
17. 1 cannabinoid receptors. Br. J. Pharmacol. 2004, 141:253-262.
18. Fedorova I., Hashimoto A., Fecik R.A., Hedrick M.P., Hanus L.O., Boger D.L., Rice K.C., Basile A.S. Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J. Pharmacol. Exp. Ther. 2001, 299:332-342.
19. Lindigkeit R., Boehme a A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., Beuerle T. Spice: a never ending story?. Forensic Sci. Int. 2009, 10.1016/j.forsciint.2009.06.008.
20. Melvin L.S., Johnson M.R., Herbert C.A., Milne G.M., Weissman A. A cannabinoid derived prototypical analgesic. J. Med. Chem. 1984, 27:67-71.
21. 1 cannabinoid receptor ligands. Mini Rev. Med. Chem. 2005, 5:631-640.
22. Razdan R.K. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 1986, 38:75-149.
23. Rapaka R.S., Makriyannis A. Structure-activity relationships of the cannabinoids. NIDA Res. Monogr. 1987, 79:1-216.
24. Howlett A.C., Johnson M.R., Melvin L.S. Classical and nonclassical cannabinoids: mechanism of action-brain binding. NIDA Res. Monogr. 1990, 96:100-111.
25. Johnson M.R., Melvin L.S., Milne G.M. Prototype cannabinoid analgetics, prostaglandins and opiates-a search for points of mechanistic interaction. Life Sci. 1982, 31:1703-1706.
26. Weissman A., Milne G.M., Melvin L.S. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J. Pharmacol. Exp. Ther. 1982, 223:516-523.
27. Huffman J.W., Dai D. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 1994, 4:563-566.
28. Huffman J.W., Padgett L.W. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem. 2005, 12:1395-1411.
29. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58:389-462.